Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 1/2 1

Status

Recruiting 4Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 6OTHER 4NIH 2NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Carcinoma, Non-Small-Cell Lung 497Neoplasms 302Breast Neoplasms 294Colorectal Neoplasms 228Neoplasm Metastasis 194Prostatic Neoplasms 175Ovarian Neoplasms 173Lung Neoplasms 159Multiple Myeloma 158Recurrence 131Melanoma 125Pancreatic Neoplasms 115Squamous Cell Carcinoma of Head and Neck 104Stomach Neoplasms 102Leukemia, Myeloid, Acute 101Endometrial Neoplasms 101Small Cell Lung Carcinoma 88Leukemia, Lymphocytic, Chronic, B-Cell 87Triple Negative Breast Neoplasms 84Lymphoma, Non-Hodgkin 84Carcinoma, Renal Cell 83Carcinoma, Hepatocellular 79Urinary Bladder Neoplasms 77Lymphoma, Large B-Cell, Diffuse 74Lymphoma, Follicular 68Advanced Solid Tumors 66Lymphoma 62Parkinson Disease 4, Autosomal Dominant Lewy Body 61Glioblastoma 58Head and Neck Neoplasms 56

Interventions

dodecyl maltoside 2Clinical Trials, Phase II as Topic 1Clinical Trials, Phase I as Topic 1BCG Vaccine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma in Situ × 90 days × Clear all
NCT06833073 2026-05-28

INTerpath-011

Merck Sharp & Dohme LLC

Phase 2 Recruiting
308 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT05951179 2026-05-18

ADVANCED-2

Protara Therapeutics

Phase 2 Recruiting
131 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT04752722 2026-04-30

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

enGene, Inc.

Phase 1/2 Recruiting
350 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT07283835 2026-04-23

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Lepu Biopharma Co., Ltd.

Phase 2 Recruiting
16 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT07480356 2026-03-18

ADVANCED-3

Protara Therapeutics

Phase 3 Not yet recruiting
284 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Neoplasms

NCT04452591 2026-03-16

BOND-003

CG Oncology, Inc.

Phase 3 Active not recruiting
190 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡